| Mr Philip Scott
| Mr Philip Scott is Non-Executive Director of Diageo Plc. He is the president elect of the Council of the Institute and Faculty of Actuaries and is a non-executive director of the Royal Bank of Scotland Group plc. He was previously chief financial officer of Aviva plc. |
| Mr Phil Thomson
| Mr PhilThomson is the Contact person at GlaxoSmithKline PLC, Phil was appointed Senior Vice President, Global Communications in August 2010, Senior Vice President at GlaxoSmithKline PLC - United States in January 2010, Global Communications. He has responsibility for Media Relations, Investor Relations, Corporate Responsibility, Global Community Partnerships, and Internal, Product, and Business Communications. Phil joined Glaxo Wellcome as a commercial trainee in 1996. |
| Ms Stacey Cartwright
| Ms Stacey Cartwright is Board Member at GlaxoSmithKline PLC. Ms. Stacey Cartwright Appointed on 1 April 2011. Stacey joined Burberry Group plc as Chief Financial Officer in 2003 and was appointed Executive Vice President, Chief Financial Officer in June 2008. Previously she held the role of Chief Financial Officer at Egg plc between 1999 and 2003, and from 1988 to 1999 she worked in various finance-related positions at Granada Group plc.Stacey is Chief Executive Officer of the Harvey Nichols Group of Companies. She served as Executive Vice President, Chief Financial Officer of Burberry Group plc until July 2013. Previously she held the role of Chief Financial Officer at Egg plc between 1999 and 2003, and from 1988 to 1999 she worked in various finance-related positions at Granada Group plc. In accordance with the UK Corporate Governance Code, the Board has determined that Stacey has recent and relevant financial experience. The Board has also agreed that she has the appropriate qualifications and background to be an audit committee financial expert as defined by the US Sarbanes-Oxley Act of 2002 |
| Mr Simon Dingemans
| Mr Simon Dingemans is Board Member at GlaxoSmithKline PLC. Mr Dingemans owns 0.0003% in GlaxoSmithKline PLC since February 2015. Mr. Simon Dingemans became Chief Financial Officer in April 2011 after joining as Chief Financial Officer Designate in January 2011. He is a member of the Board and the Corporate Executive Team.Simon joined GSK from Goldman Sachs International where he was a Managing Director and Partner. He joined Goldman Sachs in 1995, becoming Head of UK Investment Banking and later becoming a leader of the European Mergers and Acquisitions business. As part of his role at GSK, Simon is responsible for Global Finance and Core Business Services comprising a number of the company’s key global functions including Finance and Real Estate. He worked with GSK for over a decade prior to joining the company and was closely involved in a number of GSK’s most important strategic projects during that time, including the establishment of ViiV Healthcare. After receiving a Masters degree in Geography from Oxford University in 1985, Simon joined S.G. Warburg Group, the investment banking firm which specialised in mergers and acquisitions, becoming one of its youngest directors in 1994. Simon is a member of the Corporate Development Council for the National Theatre and Chairman of the 100 Group. |
| Mr Roy Anderson
| Mr Roy Anderson is Board Member at GlaxoSmithKline PLC. Mr. Roy Anderson Appointed on 1 October 2007. Sir Roy is Professor of Infectious Disease Epidemiology in the Faculty of Medicine, Imperial College, London. He is a member of the International Advisory Board of Hakluyt & Co Ltd, a Trustee of the Natural History Museum, London, a fellow (and member of the Science Policy Advisory Group) of the Royal Society and a fellow of the Academy of Medical Sciences and the Royal Statistical Society. Sir Roy is a member of the International Advisory Board of the HIV Monitoring Foundation, an Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the Institute of Medicine at the US National Academy of Sciences and the French Academy of Sciences. His former positions include Rector of Imperial College and Chief Scientific Adviser at the Ministry of Defence in the UK. |
| Mr Andrew Witty
| Mr Andrew Witty is CEO in GlaxoSmithKline PLC. Mr Witty owns 0.0016% in GlaxoSmithKline PLC since February 2015. Mr. Andrew Witty became Chief Executive Officer of GlaxoSmithKline plc on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined GSK in 1985. He has worked in the UK, South Africa, the USA and Singapore in various senior roles. In 2003, he was appointed President of GSK Europe and joined GSK’s Corporate Executive Team. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In the 2012 New Year Honours list, he was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry. Andrew served as the Lead Non-Executive Board Member for the Department for Business, Innovation and Skills to December 2013. He was also President of the European Federation of Pharmaceutical Industries and Associations until June 2013. Andrew is a Member of the UK Prime Minister’s Business Advisory Group and Member of the Global Health Innovation Advisory Board, Imperial College London. He is Chancellor of the University of Nottingham and was appointed to the UK Business Ambassador Group in January 2014. Andrew has a Joint Honours BA in Economics from the University of Nottingham. |
| Mr Tom De Swaan
| Mr Tom De Swaan was Board Member at GlaxoSmithKline PLC between 01 January 2006 and 07 May 2015. Mr. Tom De Swaan Appointed on 1 January 2006. Tom is Chairman of the Audit & Risk Committee. He is Chairman of the Supervisory Board of VanLanschot Bankiers, a member of the board of directors of Zurich Financial Services and a Non-Executive Member of KPMG Europe LLP's Public Interest Committee. Tom is also Vice Chairman of the Supervisory Board and Chairman of the Audit Committee of Royal Ahold and a member of the Supervisory Board of Royal DSM. He was previously a member of the Managing Board and Chief Financial Officer of ABN AMRO.Tom is Chairman of the Supervisory Board of Van Lanschot Bankiers and Chairman of the Board of Directors of Zurich Insurance Group. He is also a member of the Supervisory Board of Royal DSM,and a Senior Adviser to Ondra Partners.The Board has determined that Tom has recent and relevant financial experience, and agreed that he has the appropriate qualifications and background to be an audit committee financial expert. |
| Mr Crispin Davis
| Sir Crispin is board member at Vodafone Group PLC since July, 28, 2014. He is Chairman and Director of StarBev Netherlands BV, a member of Citigroup's Global Advisory Board and serves on the Council of Oxford University. Sir Crispin was previously Chief Executive Officer of Reed Elsevier plc and prior to that appointment, Chief Executive of Aegis Group plc, which he joined from Guinness plc, where he was a member of the main board and Group Managing Director of United Distillers. In his earlier career, he worked for Procter & Gamble, where he was President of the North American Food Division. He is also Chairman of the Remuneration Committee. Davis has a Bachelor degree from Oriel College at Oxford University. |
| Mr Christopher Gent
| Mr Christopher Gent is Chairman of GlaxoSmithKline PLC. Mr. Christopher Gent, appointed to the Board on 1 June 2004 and as Chairman on 1 January 2005. Sir Christopher has many years' experience of leading global businesses and a track record of delivering outstanding performance in highly competitive industries. He was appointed Managing Director of Vodafone plc in 1985 and then became its Chief Executive Officer in 1997 until his retirement in 2003. Sir Christopher has many years' experience of leading global businesses and a track record of delivering outstanding performance in highly competitive industries. He was appointed Managing Director of Vodafone plc in 1985 and then became its Chief Executive Officer in 1997 until his retirement in 2003. |
| Mr Marc Dunoyer
| Mr Marc Dunoyer was appointed Chairman of GSK Japan in January 2010 and in February 2010 to lead GSK's rare diseases business from R&D to commercialisation. He joined the Group in 1999 and was previously President, Pharmaceuticals Japan from January 2000 until May 2008. He was President, Pharmaceuticals Asia Pacific/ Japan from May 2008 until July 2010. Mr Marc Dunoyer is Executive Director and Chief Financial Officer at AstraZeneca PLC. |
| Mr Daniel Podolsky
| Mr Daniel Podolsky is Board Member at GlaxoSmithKline PLC. Mr. Daniel Podolsky, appointed on 1 July 2006. Daniel is President of the University of Texas Southwestern Medical Center and holds the Phillip O'Bryan Montgomery, Jr., M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science. He is a member of the Institute of Medicine of the US National Academy of Sciences, a member of the board of the Southwestern Medical Foundation and is a director of Antibe Therapeutics, Inc.Daniel is President of the University of Texas Southwestern Medical Center in Dallas and holds the Philip O’Bryan Montgomery, Jr M.D. Distinguished Presidential Chair in Academic Administration, and the Doris and Bryan Wildenthal Distinguished Chair in Medical Science.Daniel is a member of the National Academy of Medicine at the US National Academy of Sciences, the Council of Teaching Hospitals of the Association of Academic Medical Centers, and sits on the Board of the Southwestern Medical Foundation. He is also a Director of Antibe Therapeutics, Inc., Agilent Technologies, Inc. and a member of the National Academies of Sciences Board on Army Science and Technology. |
| Mr Moncef Slaoui
| Mr Moncef Slaoui is Board Member at GlaxoSmithKline PLC. Mr Slaoui owns 0.0009% in GlaxoSmithKline PLC since February 2015. Dr. Moncef Slaoui Appointed on 17 May 2006. Moncef joined GSK Biologicals in 1988 where he engineered the development of a robust vaccines pipeline and subsequently led Worldwide Business Development for pharmaceuticals before his appointment to lead R&D. Moncef was given overall responsibility for GSK's Oncology Business in 2010, and for GSK Vaccines in 2011. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles.Moncef joined GSK Vaccines in 1988 where he engineered the development of a robust vaccines pipeline. He then led Worldwide Business Development for pharmaceutical products before his appointment to lead R&D in 2006. He was given overall responsibility for GSK’s Oncology Business in 2010; for GSK Vaccines in 2011; and for all Global Franchises in 2012. Moncef has advised the US President’s Council of Advisors on Science and Technology and he was a member of the Board of the Agency for Science, Technology & Research (A*STAR) until January 2011. He has a PhD in Molecular Biology and Immunology from Université Libre de Bruxelles and has published more than 100 scientific papers and presentations. Prior to joining GSK, Moncef was Professor of Immunology at the University of Mons, Belgium. |
| Ms Rachel Lomax
| Ms Rachel Lomax is Board Member at HSBC Holdings PLC. Ms Rachel Lomax joined the HSBC Board of Directors in 2008. She has experience in the public and private sectors, plus a deep knowledge of the operations of the UK government and financial system.Her previous appointments include Deputy Governor, Monetary Stability, at the Bank of England (BoE) and a member of the BoE’s Monetary Policy Committee; Permanent Secretary at the UK Government Departments for Transport and Work and Pensions and the Welsh Office; and Vice President and Chief of Staff to the President of the World Bank.She is the chairman of the International Regulatory Strategy Group and director of TheCityUK; director of Bruegel, a Brussels-based European think tank; non-executive director of Arcus European Infrastructure Fund GP LLP and Heathrow Airport Holdings Limited; member of the Council of Imperial College, London; trustee of the Ditchley Foundation; and President of the Institute of Fiscal Studies. She is also a non-executive director and chairman of the corporate responsibility committee of Serco Group plc.Rachel Lomax, Former Deputy Governor, Monetary Stability at the Bank of England from 2003 to 2008, where she was responsible for monetary assessment and money market operation. Prior to joining the Bank, Ms. Lomax served as Permanent Secretary for the Department of Transport and held the same position at the Department for Work and Pensions (1999 to 2002) and the Welsh Office (1996 to 1999). She served as Vice President and Chief of Staff to the President of the World Bank from 1995 to 1996, and was Head of the Economic and Domestic Secretariat at the Cabinet Office in 1994. Ms. Lomax is an independent, non-executive director of HSBC Holdings plc, The Scottish American Investment Company PLC and BAA Limited. |
| Ms Louise Ottilie Fresco
| Ms. Louise Ottilie Fresco is Non-Executive Director of Unilever and Chairman of Unilever's Corporate Responsibility Committee. From 1990 to 1997, she was Professor of Plant Production Systems and Chair of the Department of Agronomy at Wageningen University. From 1997 to 2006, she held various positions at the Food and Agriculture Organization (FAO) of the United Nations as she was the Director of Research in the Agriculture Department of FAO. From January 2000 to May 2006 she was the Assistant Director-General of this organization, responsible for technological issues in the area of agricultural production, and later in the area of food provision. Prior to this, she was the chair of the Adviesraad voor Onderzoek naar Natuur en Milieu and the Co-Founder and Chair of the Land Use and Cover Change, project of the International Geosphere‐Biosphere Programme. Since 1986 Fresco has held various positions within the Consultative Group on International Agricultural Research, including working as an evaluator at the International Potato Institute and as a member of the Board of the West Africa Rice Development Association. She was also a Member of the Board of the Asian Vegetable Research and Development Center, Taiwan, as well as Vice-Chair of the Council of the United Nations University. In July 2014 she became President of the Executive Board of Wageningen UR. From 2009 to 2014, Ms. Louise was Supervisory Director of Rabobank and was also a Crown Appointed Member of the Social and Economic Council of the Netherlands, stepping down in 2104. In addition, she is also a Member of various entities including being a Member of the International Trilateral Commission, a Foreign Member of the Royal Swedish Academy of Agriculture and Forestry, a Corresponding Member of the Spanish Real Academia de Ingeniería and a Member of the North Netherlands Society for Sciences. She obtained Doctoral degree with honors in Tropical Agriculture in 1986 from Wageningen University, Netherlands. |
| Ms Genevieve Berger
| Ms Geneviève Berger is Chief Research and Development Officer Nationality: French. Aged 57. Appointed to ULE July 2008. Previous posts include: Chairman of the Health Advisory Board for the European Commission; Professor at the University of Paris and La Pitié- Salpêtriére Teaching Hospital; and Director General of the French Centre National de la Recherche Scientifique. Appointed Non-Executive Director of Smith & Nephew in March 2010. Ms Geneviève Berger also serves as Non-Executive Director at AstraZeneca PLC. |
| Jean-Marc Huet
| Mr. Jean-Marc Huët is the Chief Financial Officer; he was appointed as an Executive Director to the Boards of Unilever PLC and Unilever N.V. in February 2010. Prior to joining Unilever, Mr. Jean-Marc held the Executive Vice President and Chief Financial Officer roles at Bristol-Myers Squibb Company, as well as a place on the Executive Committee. Mr. Jean-Marc is also a Non-Executive Director of Delta Topco Ltd and a Member of the Supervisory Board of Heineken N.V. He was also a Non-Executive Director at Mead Johnson Nutrition in 2009. Mr. Jean-Marc was at Bristol-Myers from early 2008, prior to which he worked at Royal Numico N.V. as Chief Financial Officer and Member of the Executive Board, from 2003. There, he helped spearhead Numico’s financial restructuring, growth and acquisition strategy. Before joining Numico, Mr. Jean-Marc had a successful career at Goldman Sachs International. He joined the Bank in 1993 as an Analyst in the Investment Banking Division and became Executive Director of Investment Banking Services in 1999. And prior to that, he was Commercial Manager at Clement Trading Milan, Italy in 1991. Mr. Jean-Marc holds an MBA from INSEAD, Fontainebleau, France and a Bachelor’s degree from Dartmouth College, New Hampshire, USA. |
| Ms Murray Kessler
| Ms Murray S Kessler joined Lorillard in September of 2010 as Director, President and Chief Executive Officer, and assumed the role of Chairman of the Board on January 1, 2011. Prior to joining Lorillard, Mr. Kessler was Vice Chair of Altria Group, Inc. and President and Chief Executive Officer of UST LLC, a wholly owned subsidiary. Mr. Kessler held this position from January 2009 through June 2009, the six months following the acquisition of UST, Inc. (UST) by Altria. Prior to 2009, Mr. Kessler had served as Chairman of the Board of UST, the principal businesses of which included U.S. Smokeless Tobacco Company (USSTC) and Ste. Michelle Wine Estates, since January 2008 and President and Chief Executive Officer of UST since January 2007. He was President and Chief Operating Officer from November 2005 to December 2006 and was President of USSTC from April 2000 through October 2005. Mr. Kessler served as a director of UST from 2005 through 2008. Prior to joining UST, Mr. Kessler had over 18 years of consumer packaged goods experience with companies, including Campbell Soup and Clorox. Ms Murray S Kessler is Director at Reynolds American Inc. He was a Non-Executive Director at British American Tobacco PLC till 17 February 2025. |
| Ms Nora Mead Brownell
| Ms Nora Mead Brownell is Non-executive Director at National Grid PLC with effect from 1 June 2012. Nora Mead Brownell began her career in energy serving as a Commissioner of the Pennsylvania Public Utility Commission from 1997 to 2001. Between 2001 and 2006, she served as a Commissioner for the Federal Energy Regulatory Commission (FERC). She later co-founded the energy consulting firm, ESPY Energy Solutions, LLC. She is also the former President of the National Association of Regulatory Utility Commissioners. Nora attended Syracuse University. She also previously served as the Senior Vice President, Corporate Affairs, for Meridian Bancorp, Inc. Prior to joining Meridian in 1987, she was Deputy Executive Assistant to former Pennsylvania Governor Richard Thornburgh. In addition, Nora also served on the board of Leaf Clean Energy Company, an AIM listed company, as a non-executive director from September 2007 to November 2009 and on the board of Ener1, Inc. until 30 March 2012. Nora currently serves on the boards of the following public companies: Comverge, Inc. as the chair of the nominating and corporate governance committee and Spectra Energy Partners LP where she serves on the audit committee and conflicts committee. Nora also continues as a partner in ESPY Energy Solutions, LLC. |
| Ms Betsy Holden
| Ms Betsy Holden is Non-Executive director of Diageo plc in September 2009. She is a senior adviser to McKinsey & Company and holds non-executive directorships of MediaBank LLC, Tribune Company and Western Union Company, all in the United States. She is a member of the board of trustees at Duke University and a member of the Dean's advisory board at the Kellogg School of Management. She was formerly president, global marketing and category development and co-chief executive officer of Kraft Foods, Inc. |
| Mr Mark Cutifani
| Mr Mark Cutifani is Board Member at Anglo American PLC. Prior to that He was also CEO in Anglogold Ashanti Ltd between 2007 and 2013. He is chairman of the Executive Committee and a member of the Transformation and Human Resources Development; Safety, Health and Sustainable Development; Risk and Information Integrity; Party Political Donations Committee; and Investment Committees. Mark has considerable experience in gold mining, having been associated with the industry since 1976. Prior to joining AngloGold Ashanti, he was Chief Operating Officer at CVRD Inco, a Toronto-based company, where he was responsible for Inco’s global nickel business. |
